Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marjet A Stein-Wit

Showing results (1-10 of 6) with videos related to

Pageof 1
Sort By:
Nederlands Tijdschrift Voor Geneeskunde|April 1, 2021
[Tranexamic acid: widely applicable, few risks]Marjet A Stein-Wit, Karina Meijer
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2020
A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurementHélène L Hooimeijer, Michael V Lukens, Martijn V Verhagen, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 31, 2023
Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIIILouise H Hooimeijer, Marjet A Stein-Wit, Marja Aj Voskuilen, et al.
Research and Practice in Thrombosis and Haemostasis|September 8, 2025
High- and intermediate-risk pulmonary embolism in pediatric tertiary care centers in the NetherlandsC A M Karlijn van Balkom, Irene L M Klaassen, Marije Diender, et al.
American Journal of Hematology|April 29, 2024
Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortalityCaroline Vuong, Corien L Eckhardt, Harriët Heijboer, et al.
Research and Practice in Thrombosis and Haemostasis|April 10, 2025
Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical researchMartijn R Brands, Elisabeth M Taal, Martijn Oude Voshaar, et al.
Pageof 1

Showing results (1-10 of 6) with videos related to

Sort By:
Pageof 1
Nederlands Tijdschrift Voor Geneeskunde|April 1, 2021
[Tranexamic acid: widely applicable, few risks]Marjet A Stein-Wit, Karina Meijer
Haemophilia : the Official Journal of the World Federation of Hemophilia|April 17, 2020
A boy with joint pain associated with emicizumab treatment: The importance of plasma level measurementHélène L Hooimeijer, Michael V Lukens, Martijn V Verhagen, et al.
Clinical and Applied Thrombosis/Hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis|March 31, 2023
Occurrence of FVIII Inhibitors in Hemophilia A Patients Following an Institutional Switch to a Third Generation B-Domain-Deleted FVIIILouise H Hooimeijer, Marjet A Stein-Wit, Marja Aj Voskuilen, et al.
Research and Practice in Thrombosis and Haemostasis|September 8, 2025
High- and intermediate-risk pulmonary embolism in pediatric tertiary care centers in the NetherlandsC A M Karlijn van Balkom, Irene L M Klaassen, Marije Diender, et al.
American Journal of Hematology|April 29, 2024
Long-term follow-up of children with sickle cell disease diagnosed by newborn screening in the Netherlands: Overview of morbidity and mortalityCaroline Vuong, Corien L Eckhardt, Harriët Heijboer, et al.
Research and Practice in Thrombosis and Haemostasis|April 10, 2025
Real-world bleeding rates on emicizumab: the value of using nationwide digital treatment diary data in clinical researchMartijn R Brands, Elisabeth M Taal, Martijn Oude Voshaar, et al.
Pageof 1